非小细胞肺癌组织中K-ras表达及其临床意义

Expression of K-ras oncoprotein in human non-small cell lung cancer and its clinical significance

目的 :探讨K ras蛋白在非小细胞肺癌 (NSCLC)中的表达及其与NSCLC的发生、发展及临床预后的关系 .方法 :采用免疫组化SABC法 ,检测 37例经手术切除、病理证实的NSCLC及 9例正常肺组织K ras蛋白的表达 .结果 :K ras蛋白在NSCLC中的高表达率为 5 7% ,K ras蛋白表达与组织类型 (r =0 .5 2 9,P =0 .0 2 1 )、吸烟史 (r =0 .5 82 ,P =0 .0 0 3)、肿块大小 (r=0 .5 0 6 ,P =0 .0 4 9)、淋巴结转移 (r =0 .5 2 1 ,P=0 .0 1 8)间显著相关 (P <0 .0 5 ) .K ras高、低表达组平均生存时间分别为 1 1 .2 9和 34.31mo ,前者生存期明显缩短 (P <0 .0 1 ) .K ras表达 (P =0 .0 0 4 ,RR =4 .1 0 7)具有独立的预后意义 .结论 :K ras蛋白高表达与NSCLC的发生、发展及预后密切相关 .K ras蛋白高表达更易发生于吸烟者及肺腺癌患者 ,易发生淋巴结转移 .K

AIM: To investigate the role of K ras oncoprotein in the occurrence, development and prognosis of non small cell lung cancer (NSCLC). METHODS: Thirty seven specimens of resected, paraffin embedded NSCLC and 9 cases of normal lung tissues were examined by immunohistochemical technique(SABC methods)for the expression of K ras oncoprotein. RESULTS: Overexpression rate of K ras oncoprotein was 56.8%. Only histological type ( r = 0.529, P =0.021), smoking ( r =0.582, P =0.003), tumour size ( r =0.506, P =0.049) and lymph node involvement ( r =0.521, P =0.018) had significantly positive correlation with the overexpression of K ras oncoprotein. The mean survival time was significantly shorter in patients with K ras high expression than in patients with K ras low expression (11.29 vs 34.31 mo, P <0.01). The estimated increased relative risk for patients with K ras overexpression was 4.107. The results of the proportional hazards regression model (Cox model) showed that K ras was independental factor that had correlation with prognosis ( P = 0.004). CONCLUSION: The overexpression of K ras oncoprotein was closely related to the the occurrence、development and prognosis of NSCLC. The overexpression of K ras oncoprotein was found more frequently in smokers and patients suffering from the adenocarcinoma of lung or lymph node involvement. K ras, which is important prognostic cellular factor, may play an important role in early diagnosis for patients with NSCLC.